Search results
Showing 1936 to 1950 of 2042 results for guidelines
Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.
Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)
Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.
Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.
NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation
Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)
NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space
superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)
NICE has developed a medtech innovation briefing (MIB) on superDimension Navigation System to help diagnostic sampling of peripheral lung lesions .
care provided to people with SSNHL and on our ability to develop robust guidelines and policy. Source guidance details Comes from...
Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.